Reported Consolidated quarterly numbers for Sun Pharmaceutical Industries are:
Net Sales at Rs 7,585.25 crore in June 2020 down 9.42% from Rs. 8,374.36 crore in June 2019.
Quarterly Net Loss at Rs. 1,655.60 crore in June 2020 down 219.32% from Rs. 1,387.48 crore in June 2019.
EBITDA stands at Rs. 1,997.30 crore in June 2020 down 9.57% from Rs. 2,208.63 crore in June 2019.
Sun Pharma shares closed at 531.70 on July 31, 2020 (NSE) and has given 22.43% returns over the last 6 months and 24.59% over the last 12 months.
| Sun Pharmaceutical Industries | | Consolidated Quarterly Results | in Rs. Cr. |
|
| Jun'20 | Mar'20 | Jun'19 | | Net Sales/Income from operations | 7,467.19 | 8,078.03 | 8,259.30 | | Other Operating Income | 118.06 | 106.91 | 115.06 | | Total Income From Operations | 7,585.25 | 8,184.94 | 8,374.36 | | EXPENDITURE | | Consumption of Raw Materials | 1,518.84 | 1,209.58 | 1,335.83 | | Purchase of Traded Goods | 683.32 | 910.64 | 810.23 | | Increase/Decrease in Stocks | -232.56 | 184.59 | 311.73 | | Power & Fuel | -- | -- | -- | | Employees Cost | 1,759.04 | 1,651.89 | 1,540.40 | | Depreciation | 495.92 | 575.38 | 457.13 | | Excise Duty | -- | -- | -- | | Admin. And Selling Expenses | -- | -- | -- | | R & D Expenses | -- | -- | -- | | Provisions And Contingencies | -- | -- | -- | | Exp. Capitalised | -- | -- | -- | | Other Expenses | 2,013.10 | 2,865.23 | 2,380.56 | | P/L Before Other Inc., Int., Excpt. Items & Tax | 1,347.59 | 787.63 | 1,538.48 | | Other Income | 153.79 | 102.23 | 213.02 | | P/L Before Int., Excpt. Items & Tax | 1,501.38 | 889.86 | 1,751.50 | | Interest | 51.95 | 51.78 | 104.06 | | P/L Before Exceptional Items & Tax | 1,449.43 | 838.08 | 1,647.44 | | Exceptional Items | -3,633.33 | -260.64 | -- | | P/L Before Tax | -2,183.90 | 577.44 | 1,647.44 | | Tax | 245.91 | 83.09 | 146.06 | | P/L After Tax from Ordinary Activities | -2,429.81 | 494.35 | 1,501.38 | | Prior Year Adjustments | -- | -- | -- | | Extra Ordinary Items | -- | -- | -- | | Net Profit/(Loss) For the Period | -2,429.81 | 494.35 | 1,501.38 | | Minority Interest | 770.63 | -- | -109.17 | | Share Of P/L Of Associates | 3.58 | -1.59 | -4.73 | | Net P/L After M.I & Associates | -1,655.60 | 492.76 | 1,387.48 | | Equity Share Capital | 239.93 | 239.93 | 239.93 | | Reserves Excluding Revaluation Reserves | -- | -- | -- | | Equity Dividend Rate (%) | -- | -- | -- | | EPS Before Extra Ordinary | | Basic EPS | -6.90 | 1.67 | 5.78 | | Diluted EPS | -6.90 | 1.67 | 5.78 | | EPS After Extra Ordinary | | Basic EPS | -6.90 | 1.67 | 5.78 | | Diluted EPS | -6.90 | 1.67 | 5.78 | | Public Share Holding | | No Of Shares (Crores) | -- | -- | -- | | Share Holding (%) | -- | -- | -- | | Promoters and Promoter Group Shareholding | | a) Pledged/Encumbered | | - Number of shares (Crores) | -- | -- | -- | | - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | | - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | | b) Non-encumbered | | - Number of shares (Crores) | -- | -- | -- | | - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | | - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | | Source : Dion Global Solutions Limited |
|
_2020091018165303jzv.jpg "Decoding The World Of ETF")
CBI books UK-based Cambridge Analytica for 'illegally harvesting data' of Facebook users in India Watch more 
Ideas For Profit | Hamara Bajaj: Strong export demand of two-wheelers, long-term positive outlook Watch more 
Bharat Biotech's Covaxin found to be safe, induced immune response in Phase-1 Watch more 
5 die in Serum Institute of India fire in Pune; no impact on Covishield Watch more 
